The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 893-902

  Campos, Nicole G ^a   Maza, Mauricio ^b   Alfaro, Karla ^b   Gage, Julia C ^c   Castle, Philip E ^d,e   Felix, Juan C ^f   Cremer, Miriam L ^b,g   Kim, Jane J ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Basic Health International   (El Salvador)

^c NATIONAL CANCER INSTITUTE   (United States)

^d Global Coalition Against Cervical Cancer   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

cancer screening; decision analysis; El Salvador; HPV DNA tests; human papillomavirus (HPV); mathematical model; uterine cervical neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; EL SALVADOR; FEMALE; HUMAN; INSURANCE; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UTERINE CERVIX CANCER; WART VIRUS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOGENICITY; PATHOLOGY; PREGNANCY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIROLOGY;

ADULT; COLPOSCOPY; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; EL SALVADOR; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, THEORETICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84931563985     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29438     Document Type: Article

References (29)

1. Ferlay J, Soerjomataram I, Ervik M, et al., GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013.
2. Kitchener HC, Castle PE, Cox JT,. Chapter 7: achievements and limitations of cervical cytology screening. Vaccine 2006; 24 (Suppl 3): S3/63-70.
3. Institut Català d'Oncologia. HPV Information Centre. Available at: http://www.hpvcentre.net. Accessed on January 14, 2014.
4. Agurto I, Sandoval J, De La Rosa M, et al., Improving cervical cancer prevention in a developing country. Int J Qual Health Care 2006; 18: 81-6.
5. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: World Health Organization, 2013.
6. Gravitt PE, Coutlee F, Iftner T, et al., New technologies in cervical cancer screening. Vaccine 2008; 26 (Suppl 10): K42-52.
7. Rosenbaum AJ, Gage JC, Alfaro KM, et al., Acceptability of self-collected versus provider-collected sampling for HPV DNA testing among women in rural El Salvador. Int J Gynaecol Obstet 2014; 126: 156-60.
8. Campos NG, Burger EA, Sy S, et al., An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol 2014; 180: 545-55.
9. Goldie SJ, Kim JJ, Kobus K, et al., Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007; 25: 6257-70.
10. Kim JJ, Kuntz KM, Stout NK, et al., Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007; 166: 137-50.
11. Diaz M, Kim JJ, Albero G, et al., Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008; 99: 230-8.
12. Campos NG, Kim JJ, Castle PE, et al., Health and economic impact of HPV 16/18 vaccination and cervical cancer screening in eastern Africa. Int J Cancer 2012; 130: 2672-84.
13. World Health Organization. Macroeconomics and health: investing in health for economic development: report of the commission on macroeconomics and health. Geneva: World Health Organization, 2001.
14. Gold MR., Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
15. Tan-Torres Edejer T, Baltussen, R, Adam T, et al., eds. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003.
16. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, et al., Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr 2007; 5: 11.
17. Ferrera A, Velema JP, Figueroa M, et al., Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in honduras: a case-control study. Int J Cancer 1999; 82: 799-803.
18. Hindryckx P, Garcia A, Claeys P, et al., Prevalence of high risk human papillomavirus types among nicaraguan women with histological proved pre-neoplastic and neoplastic lesions of the cervix. Sex Transm Infect 2006; 82: 334-6.
19. Bosch FX, Manos MM, Munoz N, et al., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995; 87: 796-802.
20. Stinnett AA, Paltiel AD,. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997; 17: 483-9.
21. Qiao YL, Sellors JW, Eder PS, et al., A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-36.
22. Arbyn M, Verdoodt F, Snijders PJ, et al., Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 2014; 15: 172-83.
23. Sarian LO, Derchain S, Shabalova I, et al., Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and eastern Europe. J Med Screen 2010; 17: 195-203.
24. Cremer M, Bullard K, Maza M, et al., Cytology versus visual inspection with acetic acid among women treated previously with cryotherapy in a low-resource setting. Int J Gynaecol Obstet 2010; 111: 249-52.
25. Chirenje ZM, Rusakaniko S, Kirumbi L, et al., Situation analysis for cervical cancer diagnosis and treatment in east, central and southern African countries. Bull World Health Organ 2001; 79: 127-32.
26. Sauvaget C, Muwonge R, Sankaranarayanan R,. Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2013; 120: 218-23.
27. Gobierno de la Republica de El Salvador, Ministerio de Economia, Direccion General de Estadistica y Censos (DIGESTYC). Encuesta de hogares de propositos multiples 2012. San Salvador: DIGESTYC, 2013.
28. Chamot E, Kristensen S, Stringer JS, et al., Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review. BMC Womens Health 2010; 10: 11.
29. Herfs M, Somja J, Howitt BE, et al., Unique recurrence patterns of cervical intraepithelial neoplasia after excision of the squamocolumnar junction. Int J Cancer 2015; 136: 1043-52.